[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"myofacial-pain-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:myofacial-pain-syndrome":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,51,91,119],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":47,"locationsCount":50},"100599904","effect-of-occlusal-splint-on-head-and-neck-muscles-in-patients-with-bruxism-and-myofascial-pain-100599904",false,"NCT07090551","Effect of Occlusal Splint on Head and Neck Muscles in Patients With Bruxism and Myofascial Pain","Effect of Occlusal Splint on Head and Neck Muscles in Patients With Bruxism and Myofascial Pain: An Ultrasonographic Study","Inclusion Criteria:\n\nPatients who have presented to the Faculty of Dentistry at Istanbul University with temporomandibular disorder (TMD) complaints, Patients diagnosed with myospasm and\u002For myofascial pain syndrome in the masseter and\u002For temporalis muscles prior to treatment, Patients with no physical or mental disabilities, Patients over the age of 18, Patients who have not previously received any treatment for TMD.\n\nExclusion Criteria:\n\nPatients with any type of TMD other than masticatory muscle disorders, Patients who have previously received any form of TMD treatment, Patients under the age of 18.",true,"FEMALE","18 Years","50 Years",{"count":21,"type":22},40,"ESTIMATED","INTERVENTIONAL",[25],"NA","The study group will be selected from patients who previously presented with various temporomandibular disorder (TMD) complaints to the \"Temporomandibular Disorders Clinic\" of the Department of Complete and Removable Dentures at the Faculty of Dentistry, Istanbul University. During routine examinations, TMD-DC (Diagnostic Criteria for Temporomandibular Disorders) forms are completed to aid in achieving an accurate diagnosis. Subsequently, patients suspected of having TMD of masticatory muscle origin but without a definitive diagnosis are routinely referred for ultrasonographic (USG) imaging. Patients meeting these criteria will be included in the study.\n\nParticipants will be divided into two groups. The first group will consist of patients who have already undergone USG imaging during their routine examination, have been definitively diagnosed with masticatory muscle disorders based on clinical and radiographic findings, and have initiated routine occlusal splint therapy in the clinic. The 12-week treatment process of these patients will not be altered in any way. At the final follow-up session after the 12-week routine treatment protocol, the TMD-DC form completed at baseline will be re-administered, and the two forms will be compared to evaluate changes in symptoms and pain levels. Another USG imaging will also be performed at this session.\n\nThe second group, serving as the control group, will include patients who have previously undergone USG imaging during routine examination and have received a definitive diagnosis of masticatory muscle disorders based on clinical and radiographic evaluations, but have not yet begun treatment. Patients whose turn for treatment begins during the study period will be excluded from this group. At the end of the 12-week period, the TMD-DC form will be re-administered, and a second USG imaging will be performed. This process will not interfere with the patients' position in the treatment queue, and treatment will commence as scheduled. In the second USG session, changes in the thickness and elasticity of the masseter, temporalis, trapezius, sternocleidomastoid, and splenius capitis muscles will be assessed by comparing the two imaging records.",[28,29,30,31],"Myofacial Pain Syndrome","Local Myalgia","Masticatory Muscle Pain","Bruxism",[33,34,35,36,37,38],"myofacial pain syndrome","bruxism","ultrasonography","occlusal splint","masseter muscle","splenius capitis muscle","RECRUITING","2026-05-02",{"date":42,"type":43},"2026-05-05","ACTUAL",{"date":45,"type":43},"2025-05-05",{"date":42,"type":22},{"name":48,"class":49},"Istanbul University","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":59,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":4,"studyType":23,"phases":64,"briefSummary":65,"conditions":66,"keywords":71,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":87,"leadSponsor":89,"locationsCount":50},"100637000","evaluation-of-the-effect-of-adding-sodium-bicarbonate-to-lidocaine-in-the-treatment-of-myofascial-pain-syndrome-100637000","NCT07572994","Evaluation of the Effect of Adding Sodium Bicarbonate to Lidocaine in the Treatment of Myofascial Pain Syndrome","Evaluation of the Effect of Adding Sodium Bicarbonate to Lidocaine in the Treatment of Myofascial Pain Syndrome Using Surface Electromyography (sEMG)","BIC-LIDO-MPS","Inclusion Criteria:\n\nPatients aged 16 to 70 years Clinical diagnosis of myofascial pain syndrome (MPS) Presence of active myofascial trigger points Pain duration ≥ 3 months Pain intensity ≥ 4 on the Visual Analog Scale (VAS) Trigger points located in accessible muscles No trigger point injection in the affected area within the past 3 months Ability and willingness to provide informed consent Willingness to comply with study procedures and follow-up visits\n\nExclusion Criteria:\n\nKnown allergy or hypersensitivity to lidocaine, sodium bicarbonate, or other amide-type local anesthetics Current use of anticoagulants or presence of bleeding disorders Local or systemic infection at or near the injection site History of fibromyalgia, cancer-related pain, or central pain syndromes Major psychiatric disorders (e.g., schizophrenia, severe depression) Recent trauma or surgery to the neck, shoulder, or back within the past 6 months Use of analgesics (e.g., NSAIDs, opioids) within 5 days prior to injection Severe systemic diseases (e.g., uncontrolled diabetes, liver failure, kidney failure, severe cardiovascular disease)\n\n\\-","ALL","16 Years","70 Years",{"count":63,"type":22},30,[25],"This study is designed to evaluate a method to improve the treatment of myofascial pain syndrome (MPS), a common condition that causes muscle pain, tenderness, and reduced movement due to the presence of trigger points in muscles.\n\nA commonly used treatment for this condition is the injection of a local anesthetic called lidocaine into these trigger points to relieve pain. However, the pain relief from lidocaine alone may be temporary.\n\nIn this study, we are investigating whether adding a small amount of sodium bicarbonate to lidocaine can improve its effectiveness. Sodium bicarbonate may reduce the pain during injection and help the anesthetic work faster and possibly last longer.\n\nParticipants in this study will be randomly assigned into one of two groups:\n\nOne group will receive lidocaine alone. The other group will receive lidocaine mixed with sodium bicarbonate.\n\nThe injection will be performed once into the painful muscle trigger points under sterile conditions.\n\nPain levels will be assessed using a simple pain scale, and muscle activity will be measured using a non-invasive technique called surface electromyography (sEMG), which records muscle electrical activity. These measurements will be taken before the injection, immediately after, and during follow-up visits.\n\nParticipants may experience mild discomfort during or after the injection, but all procedures are routinely used in clinical practice. Safety measures will be in place to manage any possible side effects.\n\nThe goal of this study is to determine whether the combined injection provides better pain relief, improves muscle function, and enhances patient comfort compared to lidocaine alone.",[67,28,68,69,70],"Myofacial Pain","Myofacial Pain Syndromes","Trigger Point Pain, Myofascial","Myofascial Pain Dysfunction Syndrome",[72,73,74,75,76,77,78,79,80,81],"lidocaine","Sodium Bicarbonate","Buffered Lidocaine","Trigger Point Injection","Surface Electromyography","Myofascial Trigger Points","Muscle Pain","Injection Pain","Muscle Activity","Musculoskeletal Pain","NOT_YET_RECRUITING","2026-05-01",{"date":85,"type":43},"2026-05-07",{"date":83,"type":22},{"date":88,"type":22},"2026-10-01",{"name":90,"class":49},"Cairo University",{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":97,"eligibilityCriteria":98,"healthyVolunteers":11,"sex":59,"minAge":18,"maxAge":99,"enrollmentInfo":100,"targetDuration":4,"studyType":23,"phases":102,"briefSummary":103,"conditions":104,"keywords":106,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":50},"100619297","artificial-intelligence-clinical-decision-100619297","NCT07342790","Artificial Intelligence Clinical Decision","Utilization of Artificial Intelligence in Supporting Physical Therapy Clinical Decision in Management of Myofascial Pain Syndrome Patients","AI\u002FCDM","Inclusion Criteria:\n\n* A- Demographic: Adult individuals 18-65 both sex\n\nB- Pain Characteristics:\n\n* Localized pain.\n* Intensity: baseline pain score of 4 or higher on the VAS . C- Duration: chronic pain 3-6 months\n\nD- Prescence of Myofascial Trigger Points (MTrPs):\n\nE- Daily Functioning limitations: moderate or severe\n\nExclusion Criteria:\n\n* • Severe cognitive impairment or illness.\n\n  * Recent history of major surgery or trauma (within 3 months).\n  * Other chronic conditions that could significantly interfere with the study.\n  * Patients with fibromyalgia which may have the Key Diagnostic Criteria for Fibromyalgia Syndrome:\n\n    1. Widespread Pain Index (WPI) (appendix (2): Measures the number of painful areas across the body. A score of 7 or more indicates a higher likelihood of FMS (Wang et al. ,2025).\n    2. Symptom Severity Scale (SSS) (appendix3): Assesses the severity of symptoms such as fatigue, sleep disturbances, and cognitive difficulties. A score of 5 or more is indicative of FMS","65 Years",{"count":101,"type":22},70,[25],"The goal of this study is to investigate the effect of AI integration into clinical physical therapy clinical decision in improving cost effectiveness and clinical outcomes purposes of the study are:\n\n1. Compare the effectiveness of AI driven and human driven clinical decision in physical therapy clinical practice on management of pain in myofascial pain syndrome.\n2. Compare the effectiveness of AI driven and human driven clinical decision in physical therapy clinical practice on improving joint range of motion limitations in myofascial pain syndrome.\n3. Compare the effectiveness of AI driven and human driven clinical decision in physical therapy clinical practice on improving muscle strength in myofascial pain syndrome.\n4. Compare the effectiveness of AI driven and human driven clinical decision in physical therapy clinical practice on management of functional limitation in myofascial pain syndrome.\n5. Compare the effectiveness of AI driven and human driven clinical decision in physical therapy clinical practice on cost-effectiveness in physical therapy management of myofascial pain syndrome.",[28,105],"Clinical Decision Support",[107,108,109,110],"Clinical decision","artificial intelligence","pain","myofascial pain syndrome","2026-01-05",{"date":113,"type":43},"2026-01-15",{"date":115,"type":22},"2026-02-01",{"date":117,"type":22},"2027-04-01",{"name":90,"class":49},{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":4,"eligibilityCriteria":125,"healthyVolunteers":11,"sex":59,"minAge":18,"maxAge":99,"enrollmentInfo":126,"targetDuration":4,"studyType":23,"phases":128,"briefSummary":129,"conditions":130,"keywords":135,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":50},"100597449","efficacy-of-adding-greater-occipital-nerve-block-to-trigger-point-injection-in-patients-with-neck-pain-100597449","NCT07058636","Efficacy of Adding Greater Occipital Nerve Block to Trigger Point Injection in Patients With Neck Pain","Evaluation of the Efficacy of Adding Greater Occipital Nerve Block to Trigger Point Injection in Patients With Neck Pain and Upper Trapezius Trigger Points: A Single-Blind Randomized Controlled Trial","Inclusion Criteria:\n\n* Patients aged between 18 and 65 years.\n* Diagnosed with myofascial pain syndrome (MPS) based on the major and minor criteria described by Travell and Simons (a diagnosis requires all 5 major and at least 1 minor criterion)\n* Presence of active trigger points in the upper trapezius muscle.\n* Patients with neck pain lasting longer than 3 months.\n* Pain intensity of ≥5 on the Visual Analog Scale (VAS).\n\nExclusion Criteria:\n\n* Elderly, pediatric, pregnant, postpartum, or breastfeeding individuals; patients in intensive care; unconscious individuals; or legally incapacitated persons.\n* Known allergy to local anesthetics used in trigger point injection (e.g., lidocaine, bupivacaine) or to other drugs used (e.g., corticosteroids).\n* Patients with bleeding disorders (e.g., hemophilia, thrombocytopenia) or those currently on anticoagulant therapy.\n* Presence of active infection at or near the injection site, or any systemic infection; impaired skin integrity.\n* Patients with psychiatric disorders that may interfere with treatment response or affect study outcomes.\n* Patients with severe neurological or cardiovascular disorders, or with uncontrolled diabetes.\n* Patients with cervical disc pathologies with radiculopathy.\n* History of receiving shoulder injection, trigger point injection, dry needling, manual therapy, or electrotherapy within the past 3 months.\n* History of cervical or shoulder surgery.\n* Patients diagnosed with adhesive capsulitis, rotator cuff tendinopathy, or shoulder impingement syndrome.\n* Diagnosis of fibromyalgia.\n* Presence of active trigger points in other back muscles.",{"count":127,"type":22},60,[25],"Study Title:\n\nEvaluation of the Effectiveness of Adding Greater Occipital Nerve Block to Trigger Point Injection in Patients with Neck Pain Due to Upper Trapezius Trigger Points: A Single-Blind Randomized Controlled Trial\n\nPurpose of the Study:\n\nThis study aims to evaluate whether adding a Greater Occipital Nerve (GON) block to the standard trigger point injection treatment provides better pain relief and improves daily function in patients with neck pain caused by trigger points in the upper trapezius muscle. Trigger points are small, sensitive spots in muscles that can cause significant pain and discomfort. While both trigger point injections and GON blocks are common treatments for neck and head pain, it is not yet clear if combining these two methods offers better results.\n\nWhy is this study important? Neck pain related to trigger points in the upper trapezius muscle is a frequent problem, but there is limited research on the effectiveness of combining trigger point injections with GON blocks. This study will provide important information on whether the combination therapy can reduce pain more effectively and improve patients' quality of life and ability to perform daily activities.\n\nWho can participate?\n\nAdults aged 18 to 65 years old\n\nDiagnosed with myofascial pain syndrome (MAS) based on specific clinical criteria, including the presence of trigger points in the upper trapezius muscle\n\nExperiencing neck pain lasting longer than 3 months\n\nPain intensity rated 5 or higher on a scale of 0 to 10\n\nWho cannot participate?\n\nPregnant or breastfeeding women, children, elderly people, unconscious or critically ill patients\n\nPatients with allergies to local anesthetics or steroids\n\nIndividuals with bleeding disorders or infections near the injection site\n\nPatients with serious psychiatric or neurological diseases, or other medical conditions that may affect study results\n\nThose who have recently received similar treatments or surgery for neck or shoulder problems\n\nStudy Design and Procedures:\n\nThe study will include 60 patients meeting the criteria, randomly assigned to two groups using a balanced randomization method.\n\nGroup A will receive only trigger point injections into the upper trapezius muscle using a mixture of lidocaine and saline solution.\n\nGroup B will receive both trigger point injections and an ultrasound-guided GON block, which involves injecting a combination of local anesthetics and steroid near the greater occipital nerve to reduce pain signals.\n\nBoth groups will receive the same home exercise program focusing on stretching and strengthening neck muscles to support recovery. Patients will be encouraged to perform these exercises regularly and will be followed up weekly by phone to check their progress.\n\nThe doctor assessing patients' progress will not know which treatment the patient received, to ensure unbiased results.\n\nAssessments:\n\nPatients will be evaluated at three different times: before treatment, 1 week after treatment, and 4 weeks after treatment. Assessments include:\n\nPain intensity and quality (using Visual Analog Scale and McGill Pain Questionnaire)\n\nNeck disability and ability to perform daily activities (Neck Disability Index)\n\nQuality of life (Nottingham Health Profile)\n\nNeck joint movement and position sense (using clinical tests with special equipment)\n\nPosture evaluation (measuring head position using photography)\n\nExpected Outcomes:\n\nThe main goal is to determine if the combined treatment of trigger point injection plus GON block is more effective than trigger point injection alone in reducing pain, improving neck function, and enhancing quality of life.\n\nDuration and Follow-Up:\n\nThe study is planned to last 12 months. Patients will be closely monitored during and after treatment to ensure safety and to collect necessary data.\n\nPotential Benefits and Risks:\n\nParticipants may experience pain relief and improved function if the combined treatment is effective. Risks include mild discomfort or side effects related to injections, which will be minimized by experienced medical staff.",[131,28,69,132,133,134],"Neck Pain","Trigger Points","Upper Trapezius Trigger Points","Cervicogenic Headache",[136,110,137,138,139],"neck pain","trigger point injection","ultrasound guided occipital nerve block","upper trapezius trigger point","2025-07-01",{"date":142,"type":43},"2025-07-10",{"date":144,"type":43},"2025-04-03",{"date":146,"type":22},"2026-04",{"name":148,"class":149},"Ankara Etlik City Hospital","OTHER_GOV"]